Related Experiment Video
Updated: Jan 4, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.2K
pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
Chi Zhou1,2, Zhiting Wei1,2, Zhanbing Zhang1,2
1Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Genome Medicine
|November 1, 2019
Summary
pTuneos accurately prioritizes cancer neoantigens from sequencing data, improving cancer immunotherapy and vaccine development. This computational tool enhances neoantigen identification for personalized cancer treatments.
Area of Science:
- Computational biology
- Immunology
- Genomics
Background:
- Cancer neoantigens are crucial for effective cancer immunotherapy.
- Accurate identification of neoantigens is vital for T cell recognition.
- Existing in silico neoantigen prediction tools have limitations.
Purpose of the Study:
- To develop pTuneos, a computational pipeline for prioritizing tumor neoantigens.
- To evaluate pTuneos's performance against existing tools using various cancer datasets.
- To assess the utility of pTuneos's neoantigen immunogenicity score for survival prediction.
Main Methods:
- Developed pTuneos, a computational pipeline for neoantigen prioritization.
- Utilized next-generation sequencing data for neoantigen prediction.
- Benchmarked pTuneos against existing tools on melanoma and TIL-recognized neopeptide data.
Main Results:
- pTuneos accurately predicts MHC presentation and T cell recognition of neoantigens.
- The pipeline surpasses existing tools in neoantigen prioritization performance and speed.
- pTuneos's neoantigen immunogenicity score serves as a pan-cancer survival biomarker.
Conclusions:
- pTuneos offers a user-friendly, state-of-the-art solution for neoantigen prioritization.
- The tool facilitates research in next-generation cancer immunotherapies and personalized vaccines.
- pTuneos is publicly available for research and clinical applications.
